Treatment of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF) eradicates HIV-infection

被引:0
|
作者
Yamamoto, N. [1 ]
Ueda, M. [1 ]
Benson, C. E. [2 ]
机构
[1] Socrates Inst Therapeut Immunol, Philadelphia, PA 19126 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gc protein is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of HIV-infected patients was lost or reduced because Gc protein is deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from HIV-infected cells. Nagalase was found to be the intrinsic component of gp120. Thus, serum Nagalase activity is the sum of enzyme activities expressed in both HIV virions and envelope proteins. These Nagalase carriers are complexed with patient anti-HIV IgG. Stepwise treatment of purified Gc protein with immobilized beta-galactosidase and sialidase generated the most potent MAF (GcMAF) that can activate macrophages to develop a large amount of Fc-receptors. Less than 18 weekly administrations of 100 ng GcMAF for fourteen HIV-infected patients eradicated HIV-infection.
引用
收藏
页码:35 / +
页数:2
相关论文
共 50 条
  • [41] Prevention and treatment of surgical site infection in HIV-infected patients
    Zhang, Lei
    Liu, Bao-Chi
    Zhang, Xiao-Yan
    Li, Lei
    Xia, Xian-Jun
    Guo, Rui-Zhang
    BMC INFECTIOUS DISEASES, 2012, 12
  • [42] Prevention and treatment of surgical site infection in HIV-infected patients
    Lei Zhang
    Bao-Chi Liu
    Xiao-Yan Zhang
    Lei Li
    Xian-Jun Xia
    Rui-Zhang Guo
    BMC Infectious Diseases, 12
  • [43] Treatment of acute hepatitis C infection in HIV-infected patients
    Boesecke, Christoph
    Rockstroh, Juergen K.
    CURRENT OPINION IN HIV AND AIDS, 2011, 6 (04) : 278 - 284
  • [44] Tharapeutic efficacy of vitamin D3-binding protein-derived macrophage activating factor (GcMAF) for prostate, breast and colon cancer.
    Yamamoto, N
    Urade, M
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S90 - S90
  • [45] Treatment of hyperlipidemia in HIV-infected patients
    Geletko, SM
    ZuWallack, AR
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (07) : 607 - 614
  • [46] Treatment of depression in HIV-infected patients
    Cazzullo, CL
    Bessone, E
    Bertrando, P
    Pedrazzoli, L
    Cusini, M
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 1998, 23 (05): : 293 - 297
  • [47] Treatment of dyslipidemia in HIV-infected patients
    Sekhar, Rajagopal V.
    Balasubramanyam, Ashok
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (11) : 1845 - 1854
  • [48] Rhodococcus equi infection in HIV-infected patients
    Donisi, A
    Suardi, MG
    Casari, S
    Longo, M
    Cadeo, GP
    Carosi, G
    AIDS, 1996, 10 (04) : 359 - 362
  • [49] HIV-Infection, Atherosclerosis and the Inflammatory Pathway: Candidate Gene Study in a Spanish HIV-Infected Population
    Ibanez, Laura
    Sebastian Velli, Pablo
    Font, Roser
    Jaen, Angeles
    Royo, Josep
    Irigoyen, Daniel
    Cairo, Mireia
    De la Sierra, Alejandro
    Jesus Arranz, Maria
    Gallardo, David
    Dalmau, David
    PLOS ONE, 2014, 9 (11):
  • [50] Beneficial, effect of macrophage activating agent NK-4 on Thai HIV-infected patients
    Nakagawa, Y
    Sirivichayakul, S
    Phanuphak, P
    Suda, T
    Mito, K
    Hori, H
    ANTICANCER RESEARCH, 2003, 23 (6A) : 4389 - 4394